Andrew Nichols Selected Research

edasalonexent

1/2021	Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial.
1/2019	Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrew Nichols Research Topics

Disease

2	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 01/2021 - 01/2019
1	Needlestick Injuries (Needlestick Injury) 09/2021
1	Inflammation (Inflammations) 01/2021
1	Disease Progression 01/2021
1	Overactive Urinary Bladder (Overactive Bladder) 07/2011
1	Insulin Resistance 12/2003

Drug/Important Bio-Agent (IBA)

2	edasalonexentIBA 01/2021 - 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	NF-kappa B (NF-kB)IBA 01/2019
1	Muscarinic AntagonistsIBA 07/2011
1	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 07/2011
1	Insulin (Novolin)FDA Link 12/2003

Therapy/Procedure

1	Injections 09/2021
1	Oral Administration 01/2019